Both EZH2 and integrin α11 were found to be strong prognostic factors of relapse-free and overall survival of patients with breast cancer, but integrin α11 was a more effective therapeutic target than EZH2 for the treatment of drug-resistant breast cancer. The gene discussed is EZH2; the disease is breast carcinoma.